Johnson & Johnson Raises Full-Year Guidance on Second-Quarter Profit of $2.90 Per Share and $25.3 Billion in Sales

businesscompany-earnings 3 posts · 3 accounts

Johnson & Johnson reported second-quarter adjusted earnings of $2.90 a share on sales of $25.31 billion, beating analyst estimates and surpassing the $25 billion quarterly sales mark.

The company raised its full-year revenue forecast to $100.8 billion to $101.4 billion and lifted earnings guidance to $11.60 to $11.75 a share. Growth in the medicine division, led by oncology and immunology products, offset a slight miss in Medtech sales. The updated guidance supports a path to $100 billion in annual revenue for the first time in the company's 140-year history.

From the sources (3 posts)

@wallstengine

$JNJ Q2’26 EARNINGS HIGHLIGHTS 🔹 Sales: $25.31B (Est. $25.02B) 🟢; +6.6% YoY 🔹 Adj EPS: $2.90 (Est. $2.86) 🟢; +4.7% YoY 🔹 Adj Net Earnings: $7.08B; +5.7% YoY FY26 Guide: 🔹 Sales: $100.8B to $101.4B (Est. $101.06B) 🟡; +7.3% YoY 🔹 Adj EPS: $

@firstsquawk

Johnson & Johnson Q2 2026 Earnings -Adj EPS $2.90 (est $2.85) -Sales $25.31B (est 25.04B) -Medtech Sales $8.93b (est $8.99b) -Medicine Revenue $16.38b (est $16.12b) -Sees FY Sales $100.88 To $101.48, Saw $100.3b To $101.3b -Sees FY Ad

@stockmktnewz

JOHNSON & JOHNSON $JNJ JUST REPORTED EARNINGS EPS of $2.90 beating expectations of $2.85🟢 Revenue of $25.3B beating expectations of $25B🟢

BlackRock Tops Earnings Estimates, Drives Assets to Record $15.34 Trillion on Strong Inflows Abbott Beats Second-Quarter Profit and Sales Estimates and Raises Full-Year Outlook on $12.6 Billion Revenue